6: A phase 2 randomized, double-blind, placebo-controlled study to evaluate the effectiveness and safety of single, oral doses of SYM-1219, a granule formulation containing 1 and 2 gram doses of secnidazole, for the treatment of women with bacterial vaginosis

      SYM-1219, a granule formulation of secnidazole, a 5-nitroimidazole with a longer half-life (∼17 hr) than metronidazole (∼8 hr), is being developed to treat bacterial vaginosis (BV). Secnidazole has been used outside the US to treat protozoal and anaerobic infections. The objectives of this study were to compare the efficacy and safety of SYM-1219 granules containing 1 or 2 grams of secnidazole to placebo for the treatment of women with BV.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect